NAYA Biosciences has announced the expansion of its bifunctional antibody pipeline to include a novel PD-1 x VEGF tetravalent antibody, NY-500, targeted at hepatocellular carcinoma (HCC) and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results